TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$140 Million

Prime Medicine, Inc.

Follow-on Offering

Bookrunner, February 2024

Prime Medicine, Inc.

Prime Medicine, Inc. (“Prime Medicine” or the “Company”) (NASDAQ: PRME) is a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies to address the widest spectrum of diseases. The Company is deploying its Prime Editing technology, which they believe is a versatile, precise, and efficient gene editing technology.